Zobrazeno 1 - 10
of 40
pro vyhledávání: '"P Soto Escribano"'
Autor:
Rosario Medina-Medina, Eva Iglesias-Flores, Jose M. Benítez, Sandra Marín-Pedrosa, Isabel Salgueiro-Rodríguez, Clara I. Linares, Sandra González-Rubio, Pilar Soto-Escribano, Beatriz Gros, Manuel L. Rodríguez-Perálvarez, José L. Cabriada, María Chaparro, Javier P. Gisbert, Eduardo Chicano-Gálvez, Ignacio Ortea, Gustavo Ferrín, Valle García-Sánchez, Patricia Aguilar-Melero
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 10, p 8695 (2023)
Therapy with anti-tumor necrosis factor (TNF) has dramatically changed the natural history of Crohn’s disease (CD). However, these drugs are not without adverse events, and up to 40% of patients could lose efficacy in the long term. We aimed to ide
Externí odkaz:
https://doaj.org/article/fc826a181fd145d4b5fd4b73a2930031
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A Aparicio-Serrano, J M Zamora Olaya, D S Ortiz Chimbo, M I Rodríguez Tirado, A Gómez Pérez, P Soto Escribano, S Marín Pedrosa, E Iglesias Flores, J M Benítez
Publikováno v:
Journal of Crohn's and Colitis. 16:i351-i352
Background To evaluate the short and long-term effectiveness and safety of ustekinumab (UST) in a real-world multirefractory Crohn’s disease (CD) cohort. Methods An observational, retrospective and single-center study of CD patients treated with US
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e54735253a907e9bbb992c7fa0cf015c
https://doi.org/10.1093/ecco-jcc/jjab232.461
https://doi.org/10.1093/ecco-jcc/jjab232.461
Autor:
C J Suarez Ferrer, F Mesonero, B Caballol, M P Ballester, I Baston Rey, A Castaño Garcia, J Miranda Bautista, R Saiz Chumillas, J M Benitez, L Sanchez Delgado, A Lopez-Garcia, C Rubin de Celix, M D Martin-Arranz, A Lopez Sanroman, A Fernandez-Clotet, V Merino Murgui, C Calviño Suarez, P Florez, M E Lobato Matilla, B Sicilia, P Soto Escribano, C Maroto Martin, I Alonso Abreu, L Melcarne, P G Elena, E Iyo, A Elosua Gonzalez, E Saiz, L Hernandez Villalba, P Perez Galindo, L Torrealba Medina, S Monsalve Alonso, J A Olmos Jerez, C Dueñas Sadornil, M Barreiro-De Acosta
Publikováno v:
Journal of Crohn's and Colitis. 16:i478-i479
Background Biological treatments used for the treatment of inflammatory bowel disease (IBD) have demonstrated their efficacy and safety, although these results were obtained from studies that mostly include young people generally included in clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::142337daebd1e289a6c8aa13b5262b8b
https://doi.org/10.1093/ecco-jcc/jjab232.650
https://doi.org/10.1093/ecco-jcc/jjab232.650
Autor:
C J Suarez Ferrer, F Mesonero, B Caballol, M P Ballester, I Baston Rey, A Castaño Garcia, J Miranda Bautista, R Saiz Chumillas, J M Benitez, L Sanchez Delgado, A Lopez-Garcia, C Rubin de Celix, A Lopez Sanroma, M D Martin-Arranz, A Fernández-Clotet, V Merino Murgui, C Calviño Suárez, P Florez, M E Lobato matilla, B Sicilia, P Soto Escribano, C Maroto Martin, I Alonso Abreu, L Melcarne, R Plaza Santos, M Marques Cami, A Caballero Mateos, C Gómez Díez, M Calafat, H Alonso Galan, P Vega Villaamil, B Castro Senosiain, A Guerro Moya, C Y Rodriguez Diaz, K Spicakova, N Manceñido Marcos, G Molina, L De Castro, M Mañosa Ciria, M Barreiro-De Acosta
Publikováno v:
Journal of Crohn's and Colitis. 16:i400-i401
Background The most feared adverse events related to biological treatment in patients with inflammatory bowel disease (IBD) are the development of tumors and / or serious infections. These events are generally more frequent in elderly patients, so th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e55f479ae9ddc2a404bc8ee126606cb
https://doi.org/10.1093/ecco-jcc/jjab232.537
https://doi.org/10.1093/ecco-jcc/jjab232.537
Autor:
J M Zamora Olaya, A Aparicio-Serrano, A Gómez Pérez, D S Ortiz Chimbo, M I Rodríguez Tirado, P Soto Escribano, S Marín Pedrosa, E Iglesias Flores, J M Benítez
Publikováno v:
Journal of Crohn's and Colitis. 16:i467-i468
Background The aim of the present study is to evaluate the impact of anti-TNF drugs on the need for surgery among patients with ulcerative colitis (UC). Secondary objectives: to compare needs for medical treatment before surgery, indications for surg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e260ad6a7e1973d432ca7f34c0ac4301
https://doi.org/10.1093/ecco-jcc/jjab232.634
https://doi.org/10.1093/ecco-jcc/jjab232.634
Publikováno v:
Journal of Crohn's and Colitis. 16:i486-i486
Background Multiple adalimumab (ADA) biosimilars are now available since they were first commercialized in 2019 after having proved their safety and effectiveness in rheumatoid diseases. However, real data in inflammatory bowel disease (IBD) remain s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d33aeac19ae98b64fa1764a9da4199f8
https://doi.org/10.1093/ecco-jcc/jjab232.661
https://doi.org/10.1093/ecco-jcc/jjab232.661
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.